Skip to content
Buy This GLP
← Research
Evidence

Which GLP-1 Pills Are in Development? Aleniglipron and Elecoglipron

See which oral GLP-1 drugs are still in trials, which program stopped, and which tablets are already FDA-approved.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
Aleniglipron, week 36, placebo-adjusted45 mg−8.2%90 mg−9.8%120 mg−11.3%ACCESS phase 2b · 230 adults randomized.

Aleniglipron and elecoglipron are investigational oral GLP-1 drugs that have reached phase 3 [2] [5]. If you are comparing GLP-1 pill and injection prices, distinguish approved products from drugs still in trials. A trial result cannot establish an approval date or retail price.

Aleniglipron

The ACCESS phase 2b trial randomized 230 adults with overweight or obesity [1]. At 36 weeks, the 45 mg, 90 mg and 120 mg groups lost an estimated 8.2, 9.8 and 11.3 percentage points more than placebo, respectively. In its November SEC filing, Structure Therapeutics said its phase 3 ACCOMPLISH program was underway [2].

Elecoglipron

Researchers studied blood glucose and weight in separate phase 2 programs. Our elecoglipron guide gives more context on its early results. SOLSTICE primarily measured hemoglobin A1C in adults with type 2 diabetes [3]. VISTA assessed weight outcomes in adults with overweight or obesity [4]. AstraZeneca is testing the drug for weight management in registered phase 3 studies [5].

TERN-601

Terns Pharmaceuticals stopped developing TERN-601 after liver enzyme elevations in three phase 2 participants [6]. One event was reported as serious drug-induced liver injury. The findings concern this candidate and do not establish the liver risk of other GLP-1 pills.

Which pills are already approved in the US?

Wegovy tablets contain semaglutide, and Foundayo tablets contain orforglipron [7] [8]. The FDA has approved both for weight management in eligible adults. Each has its own label and instructions.

Frequently asked

Which GLP-1 pills are in phase 3 development?
Aleniglipron and elecoglipron are in phase 3 development as of November 2026.
Why did TERN-601 development stop?
The sponsor ended development primarily because of liver safety findings in phase 2.
Which GLP-1 pills are already FDA-approved for weight management?
Wegovy tablets contain semaglutide. Foundayo tablets contain orforglipron. Both are approved for weight management in eligible adults.

Sources

  1. [1] Rosenstock J, Lingvay I, Ryan D, et al. (2026). Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity Nature Medicine. PMID 42249138
  2. [2] Structure Therapeutics Inc. (2026). Form 10-Q for quarter ended September 30, 2026 U.S. Securities and Exchange Commission. Source
  3. [3] Aroda VR, Davies MJ, Maaske J, et al. (2026). Elecoglipron in adults with type 2 diabetes (SOLSTICE) The Lancet. PMID 42259343
  4. [4] Davies MJ, Aroda VR, Rosenstock J, et al. (2026). Elecoglipron in adults with obesity or overweight (VISTA) The Lancet. PMID 42259337
  5. [5] AstraZeneca (2026). Phase 3 master protocol for elecoglipron in weight management (NCT07667803) ClinicalTrials.gov. Source
  6. [6] Garvey WT, et al. (2026). Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight Obesity. PMID 42528333
  7. [7] Novo Nordisk Inc. (2026). Wegovy prescribing information DailyMed, U.S. National Library of Medicine. Source
  8. [8] Eli Lilly and Company (2026). Foundayo prescribing information U.S. Food and Drug Administration. Source

Where to get it

Price the oral sellers

Switch the desk to tablets and it prices the oral product itself, never a figure borrowed from the same seller's injection page.

Open the price desk →

More in Evidence